Source and scope
This summary is bounded to the recommendations, population and decisions covered by Practice Guidelines: Evaluation of abnormal liver enzyme tests. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CAG liver tests
Source-attributed clinical priorities
- Interpret the hepatocellular, cholestatic or isolated bilirubin pattern and compare with prior results and clinical context.
- Review alcohol, medicines, metabolic risk, viral exposure and autoimmune or inherited clues and order targeted testing.
- Escalate jaundice with systemic illness, coagulopathy, encephalopathy or marked acute injury and refer persistent unexplained abnormalities.
- Interpret the pattern and magnitude of abnormality rather than responding to each analyte in isolation.
sources for this section:CAG liver tests
Practical assessment and management workflow
1
Repeat or confirm tests when appropriate and compare alanine aminotransferase, alkaline phosphatase, bilirubin, INR and albumin.
2
Review alcohol, metabolic risk, viral exposure, medicines, supplements and autoimmune or inherited clues.
3
Order targeted serology and ultrasound according to hepatocellular, cholestatic or bilirubin pattern.
4
Calculate fibrosis risk where relevant and refer persistent, unexplained or high-risk disease.
sources for this section:CAG liver tests
Safety, red flags and urgent escalation
- Encephalopathy, coagulopathy, hypoglycemia or rapidly rising jaundice needs emergency hepatology care.
- Stop a likely hepatotoxic agent urgently when severe drug-induced liver injury is suspected and seek advice.
- Do not interpret a normal aminotransferase as excluding advanced chronic liver disease.
sources for this section:CAG liver tests
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CAG liver tests
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CAG liver tests
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Association of GastroenterologyPractice Guidelines: Evaluation of abnormal liver enzyme testsaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.